'Egfr mutant' presentation slideshows

Using Non-targeted Therapies in Targeted Lung Cancer Populations

Using Non-targeted Therapies in Targeted Lung Cancer Populations. Nathan Pennell, M.D., Ph.D. September 6, 2014. Objectives. Discuss the role of chemotherapy in molecularly defined populations Discuss the addition of chemo and/or bevacizumab (Avastin) to targeted therapy

647 views • 42 slides

Repeat Biopsies and the Potential Value of Biologically-Informed Acquired Resistance Therapy

429 views • 29 slides

557 patients included in the ITT efficacy analysis 555 assessed for EGFR expression

1861 patients screened 1688 with tumors suitable for EGFR expression assessment. 321 excluded 183 did not meet inclusion criteria 79 refused to participate 59 other reasons. 1442 patients with EGFR-expressing tumors. 4 EGFR status unknown. 1125 randomly assigned ITT population.

183 views • 1 slides